RU2017124141A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017124141A3 RU2017124141A3 RU2017124141A RU2017124141A RU2017124141A3 RU 2017124141 A3 RU2017124141 A3 RU 2017124141A3 RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A3 RU2017124141 A3 RU 2017124141A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017124141A RU2017124141A (ru) | 2019-01-10 |
| RU2017124141A3 true RU2017124141A3 (enExample) | 2019-06-19 |
| RU2725807C2 RU2725807C2 (ru) | 2020-07-06 |
Family
ID=56108081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017124141A RU2725807C2 (ru) | 2014-12-08 | 2015-12-08 | Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (enExample) |
| EP (1) | EP3230311B1 (enExample) |
| JP (2) | JP7095992B2 (enExample) |
| KR (1) | KR102654033B1 (enExample) |
| CN (1) | CN107108718B (enExample) |
| AU (1) | AU2015360642B2 (enExample) |
| CA (1) | CA2968987C (enExample) |
| NZ (1) | NZ732073A (enExample) |
| RU (1) | RU2725807C2 (enExample) |
| SG (1) | SG11201704124YA (enExample) |
| WO (1) | WO2016094456A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| JP7095992B2 (ja) | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| CN112512573B (zh) * | 2018-05-23 | 2026-02-27 | 百提威生技股份有限公司 | 双特异性t细胞衔接蛋白及其用途 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AU2021301788A1 (en) * | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IE920716A1 (en) * | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| CA2447695C (en) * | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| AU2004215133B2 (en) * | 2003-02-27 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| BRPI0507649A (pt) * | 2004-02-16 | 2007-07-10 | Micromet Ag | molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| WO2008091682A2 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble fc gamma r1a for reducing inflammation |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| US20120294857A1 (en) * | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| AU2011349049B2 (en) * | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| BR112014014418A2 (pt) * | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | proteínas de fusão fc de receptor igf solúvel e usos das mesmas |
| JP6407726B2 (ja) * | 2012-03-01 | 2018-10-24 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | 長寿命ポリペプチド結合分子 |
| JP7095992B2 (ja) | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
-
2015
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220235115A1 (en) | 2022-07-28 |
| JP7095992B2 (ja) | 2022-07-05 |
| EP3230311B1 (en) | 2022-01-26 |
| CN107108718B (zh) | 2022-07-22 |
| US20170362299A1 (en) | 2017-12-21 |
| WO2016094456A1 (en) | 2016-06-16 |
| US12247062B2 (en) | 2025-03-11 |
| CA2968987A1 (en) | 2016-06-16 |
| JP2018502068A (ja) | 2018-01-25 |
| JP2021035994A (ja) | 2021-03-04 |
| NZ732073A (en) | 2019-04-26 |
| CA2968987C (en) | 2022-05-10 |
| EP3230311A4 (en) | 2018-05-30 |
| EP3230311A1 (en) | 2017-10-18 |
| RU2017124141A (ru) | 2019-01-10 |
| CN107108718A (zh) | 2017-08-29 |
| KR102654033B1 (ko) | 2024-04-02 |
| AU2015360642A1 (en) | 2017-06-08 |
| AU2015360642B2 (en) | 2019-04-04 |
| KR20170089003A (ko) | 2017-08-02 |
| RU2725807C2 (ru) | 2020-07-06 |
| SG11201704124YA (en) | 2017-06-29 |